SK biocience Secures Major Funding to Boost Vaccine Development in South Korea

SK bioscience Secures Major Funding to Boost Vaccine Development

In a significant step for the biotechnology sector in South Korea, SK bioscience has received official approval from its Board of Directors for a substantial funding initiative. This follows the recent announcement from the Financial Services Commission, which identified SK bioscience as a key beneficiary of the Korea Growth Fund, granting the company KRW 300 billion (approximately USD 230 million) to expand its research and development (R&D) capabilities and accelerate the commercialization of its vaccine, GBP410.

SK bioscience has made history by becoming the first Korean company focused on novel drug and vaccine development to be selected for the Korea Growth Fund, which is aimed at promoting advanced industries including biotechnology. The financial backing will be instrumental in furthering the late-stage development of its innovative pneumococcal vaccine candidate GBP410, which is being co-developed with Sanofi. This vaccine is currently undergoing Phase 3 clinical trials, and the company is optimistic about announcing top-line results in the latter half of next year.

The funding acquired from the Korea Growth Fund will not only assist in the ongoing R&D of GBP410 but will also enhance SK bioscience's manufacturing capabilities and prepare the company for future commercialization endeavors. The funding decision is a clear recognition of the Korean government's support for domestic biotech enterprises, highlighting the importance of investing in R&D capabilities and innovative pipelines, rather than only manufacturing infrastructure.

The Korea Growth Fund is a public-private financing initiative that has been designed to assist strategic sectors, with considerable attention directed toward industries that promise significant future growth, such as AI, semiconductors, and biotechnology. It aims to provide long-term capital for high-potential projects, particularly those that have the capacity to compete on a global scale.

Beyond the GBP410 vaccine project, SK bioscience is committed to expanding its portfolio of infectious disease-focused products. The company is also working on universal COVID-19 vaccines, microneedle patch technologies for influenza vaccines, RSV preventive antibody therapeutics, and an array of mRNA vaccine platforms.

In a recent strategic move, SK bioscience relocated its headquarters and R&D center to Songdo, Incheon, effectively integrating various functions such as R&D, process development, business development, and marketing. This shift is aimed at enhancing the global competitive stance of the company, allowing it to respond effectively to evolving global health challenges.

Jaeyong Ahn, the CEO of SK bioscience, expressed gratitude for the government's recognition of the company's capabilities. He stated, "Being selected as a beneficiary of the Korea Growth Fund reflects recognition of our vaccine development capabilities and global business competitiveness. We will continue investing in key pipeline development and manufacturing infrastructure to strengthen Korea's vaccine sovereignty and enhance preparedness for future infectious disease outbreaks."

Furthermore, SK bioscience continues to play a pivotal role in Korea’s national health framework by supplying vaccines for pneumonia and varicella through the National Immunization Program. The company is also advancing a cell culture-based vaccine for avian influenza as part of an initiative led by the government, further highlighting its commitment to public health security.

As an innovative entity in the field of biotechnology, SK bioscience remains dedicated to making vaccines accessible worldwide. Its collaborative efforts with various stakeholders, including government bodies, healthcare providers, and medical experts, underline its commitment to improving global health outcomes. The company's focus on R&D aims not only at immediate health challenges but at ensuring long-term solutions for infectious disease management, ultimately fostering a healthier future for all.